Now let me produce the final consolidated review.

## Summary

This paper proposes a weighted conformal prediction procedure for constructing lower prediction bounds (LPBs) for counterfactual survival outcomes under general right-censored data. The key idea is to transform the coverage problem into a weighted conformal inference problem, using inverse probability weighting to handle censoring and treatment assignment. Under the strong ignorability assumption, the method achieves coverage guarantees with a clean error decomposition (Theorem 4.1) and a doubly robust property (Theorem 4.2). The method is evaluated on synthetic and real clinical lung cancer data across multiple radiochemotherapy regimens.

## Strengths

1. **Novel problem formulation**: The paper addresses a genuine gap — prior conformal survival methods (Candès et al., 2023; Gui et al., 2024; Davidov et al., 2025) either handled only Type-I censoring or provided only PAC-type guarantees, and none handled counterfactual outcomes. Extending distribution-free marginal (not merely PAC) coverage guarantees to counterfactual survival outcomes under general right-censoring is a worthwhile and non-trivial contribution.

2. **Clean theoretical separation of coverage error**: Theorem 4.1 provides a finite-sample bound $\mathbb{P}(T(w) \geq \tilde{L}) \geq 1 - \alpha - \frac{1}{2}\mathbb{E}[|\hat{\omega}(X) - \omega(X)|]$ that cleanly isolates the impact of density ratio estimation error on coverage. This decomposition is more transparent and interpretable than PAC-type bounds from prior work, and it clarifies what needs to be estimated well for the method to work.

3. **Doubly robust property**: Theorem 4.2 shows asymptotic validity when either the weight function $\hat{\gamma}(x)$ or the quantile estimator $\hat{q}_\alpha^{(w)}(x)$ is consistently estimated (conditions A1/A2). This is a meaningful robustness property that goes beyond standard conformal prediction.

4. **Empirical validation on real clinical data**: The application to 541 NSCLC patients across four radiochemotherapy regimens (radiotherapy technique, concurrent/induction/consolidation chemotherapy) demonstrates practical utility. The LPB results are consistent with known clinical evidence (VMAT > IMRT per Hunt et al., 2022; induction/concurrent chemotherapy benefits per Curran et al.; Aguado et al., 2022).

5. **Outlier robustness**: Figure 3 shows that under distributional perturbations (up to N(20,2) outliers), the proposed method maintains coverage near the 90% target while PAC-type baselines (Focus, Fused) degrade substantially. This experimentally confirms a claimed advantage of marginal over PAC-type coverage.

## Weaknesses

### Fatal
None.

### Major

1. **Flawed derivation in Equation (1)** : The central chain of equalities/inequalities connecting $\alpha$ to the weighted conformal objective has two specific mathematical problems. (a) Step (ii) claims to follow from the "tower property," but multiplying $\mathbb{P}(T \leq \ldots \mid X, W=w)$ by $1/p(e=1\mid X,W=w)$ does **not** preserve equality in general — this is not a tower-property operation. The correct step would use the IPCW identity $\mathbb{E}[\mathbb{I}(T \leq \cdot)] = \mathbb{E}[\mathbb{I}(T \leq \cdot, e=1)/p(e=1\mid X,W)]$, which directly gives $\mathbb{P}(T \leq \ldots, e=1\mid X,W)/p(e=1\mid X,W)$ rather than the paper's expression. (b) Step (iii) states an inequality in the wrong direction: $\mathbb{P}(A) \geq \mathbb{P}(A \cap B)$ implies $\mathbb{P}(A)/p(e=1) \geq \mathbb{P}(A \cap B)/p(e=1)$, not $\leq$. While the overall conclusion (that weighted conformal calibration can provide coverage) is likely still correct when the derivation is properly fixed using IPCW, the mathematics **as presented** is incorrect. The paper cites Lemma A.1 (stripped appendix) for step (iii), but no lemma can reverse the basic inequality $\mathbb{P}(A) \geq \mathbb{P}(A \cap B)$. This undermines trust in the theoretical development and needs correction in a revision.

2. **The proven coverage guarantee targets a different distribution than claimed**: The stated goal (Section 3, line 64) is coverage for $\mathbb{P}_X \times \mathbb{P}_{T(w)\mid X}$, but Theorems 4.1 and 4.2 guarantee coverage for $\mathbb{P}_X \times \mathbb{P}_{T(w)\mid X, e=1}$. Under independent censoring, $\mathbb{P}_{T(w)\mid X, e=1} \neq \mathbb{P}_{T(w)\mid X}$ in general because observing an uncensored event ($e=1$) is informative about $T(w)$ even when $T(w) \perp C \mid X$. The paper acknowledges this shift in passing (line 140: "it is sufficient for the LPB to satisfy the coverage guarantee for $\mathbb{P}_X \times \mathbb{P}_{\tilde{T} \mid W=w, e=1, X}$") but provides no proof of sufficiency. The derivation chain in (1) is supposed to justify this shift, but as noted above, it is flawed. This is a substantive gap between the paper's claims and what is actually proven.

3. **Overclaimed "exact" guarantee**: The paper repeatedly claims "exact marginal coverage" (abstract, introduction, Section 4.2, discussion), but Theorem 4.1 shows $\mathbb{P}(T(w) \geq \tilde{L}) \geq 1 - \alpha - \frac{1}{2}\mathbb{E}[|\hat{\omega}(X) - \omega(X)|]$. This is an approximate guarantee with a penalty term that only vanishes as weight estimation improves. The contrast with PAC guarantees is meaningful — this bound applies to the marginal distribution rather than "with high probability" — but calling it "exact" is misleading. The paper should either qualify the term explicitly (e.g., "exact up to weight estimation error") or replace it.

### Minor

1. **Below-nominal coverage in one experimental setting**: In Setting 6 (Figure 1), the proposed method's median coverage falls below the 90% target. The paper acknowledges this but does not discuss whether the deviation is within the margin implied by the error term in Theorem 4.1 or whether it indicates a systematic issue.

2. **Data-dependent $\tau$ optimization may affect coverage guarantees**: The LPB optimization step (Section 4.1) selects $\tau^*(x)$ per test point to maximize $\tilde{q}_\tau^{(w)}(x) - c_{1-\alpha}^{(w)}(\tau)(x)$. The paper states that "our procedure yields a prediction set that satisfies the coverage guarantee for any $\tau \in (0,1)$," but this is stated for a fixed $\tau$ used throughout calibration. If $\tau$ is chosen per test point based on the same calibration output, the guarantee for a fixed $\tau$ does not automatically apply to the optimized LPB. The paper should address this or restrict optimization to a held-out set.

3. **Limited description of baselines**: The "Focus" and "Fused" baselines from Davidov et al. (2025) are not described in sufficient detail to assess implementation fairness. It is unclear whether the same quantile regression estimator is used across all methods or how hyperparameters are selected.

4. **Small real-data test set**: With 541 patients split 50/10/30/10, only ~54 test samples per trial are available. The coverage estimates have large standard errors (~4 percentage points for 90% nominal coverage), making it difficult to assess whether observed coverage deviations are within sampling error.

### Trivial
None.

## Nice-to-Haves

- A corrected derivation in Equation (1) using proper IPCW reasoning would strengthen the paper considerably.
- The paper could more clearly state upfront that the target distribution is $\mathbb{P}_X \times \mathbb{P}_{T(w)\mid X, e=1}$ and discuss the relationship to the population-level target.
- Explicitly bounding or characterizing the weight estimation error term $\frac{1}{2}\mathbb{E}[|\hat{\omega} - \omega|]$ under specific estimation strategies would make the guarantee more actionable.

## Removed Points

- **Harsh critic's claim that the corrected inequality in step (iii) makes the procedure anti-conservative**: This is incorrect. The corrected direction ($\geq$) would give $\alpha \geq \mathbb{E}[\omega(X)\cdot\mathbb{I}(V \geq c)]$, meaning weighted miscoverage $\leq \alpha$, which supports conservative coverage (the desired direction). The harsh critic's conclusion that this "reverses" the guarantee is based on a misreading of the chain.
- **Harsh critic's claim about the tower property being inapplicable**: The critic is right that the "tower property" justification is insufficient, but this is a subset of the broader issue captured in Major Weakness 1. The point is subsumed.
- **Harsh critic's complaint about data-dependent $\tau$ (as a structural/fatal issue)**: Demoted to Minor because the paper acknowledges the guarantee holds for any fixed $\tau$, and the gap (per-test-point optimization) is an addressable extension, not a fatal contradiction.
- **Strength Finder's claim about "exact marginal coverage"**: This conflicts with the verified weakness about overclaimed exactness and is removed.
- **Strength Finder's claim about "empirical validation shows LPB results align with known clinical evidence"**: This is kept (Strengths #4) but toned down from the Strength Finder's effusive language.

## Novel Insights

The harsh critic correctly identifies that the inequality direction in step (iii) of Equation (1) is wrong and that step (ii) is not justified by the tower property. However, the critic's conclusion that the corrected inequality would make the procedure anti-conservative is itself incorrect — the corrected direction actually supports the desired conservative coverage. The deeper issue is that the paper needs a properly IPCW-based derivation, not just a sign flip. Additionally, the target-distribution mismatch ( $\mathbb{P}_{T(w)\mid X, e=1}$ vs. $\mathbb{P}_{T(w)\mid X}$ ) is a real concern that the paper acknowledges but does not fully resolve; this is characteristic of survival analysis with censored data, but the paper's framing as "exact coverage" for population-level counterfactuals elides this subtlety.

## Suggestions

1. **Fix the derivation in Equation (1)** : Replace the current chain with a proper IPCW-based derivation: $\alpha = \mathbb{E}[\mathbb{I}(T(w) \leq \hat{q}_\tau^{(w)}(X) - c)] = \mathbb{E}[\mathbb{I}(T \leq \ldots, e=1, W=w) / \gamma(X)]$, using the standard identity $\mathbb{E}[\mathbb{I}(T \leq t)] = \mathbb{E}[\mathbb{I}(T \leq t, e=1)/\mathbb{P}(e=1\mid X)]$ under independent censoring. This eliminates both the unjustified step (ii) and the wrong-direction inequality in step (iii).

2. **Be precise about the target distribution throughout the paper**: Either (a) state upfront that the guarantee is for $\mathbb{P}_X \times \mathbb{P}_{T(w)\mid X, e=1}$ (i.e., coverage for the uncensored subpopulation) and discuss why this is clinically meaningful, or (b) provide a formal argument for why the guarantee transfers to $\mathbb{P}_X \times \mathbb{P}_{T(w)\mid X}$.

3. **Qualify the "exact" language**: Replace "exact marginal coverage" with "distribution-free marginal coverage guarantee up to weight estimation error" or similar throughout.

4. **Address the data-dependent $\tau$ optimization**: Either prove that the guarantee holds uniformly over $\tau$ selection, or restrict $\tau$ optimization to a separate validation fold.

5. **Provide standard errors or confidence intervals** for coverage estimates in the experiments, particularly for the real-data analysis with small test samples.

## Score and Decision

**Round 1 bracket:** 4.5–6.0, based on comparison with weak anchors (2.0–3.25, papers with clear reject-level issues) and middle anchors (5.5–7.0, conformal+causal and conformal+survival papers).

**Round 2 anchors consulted:**
- **JQtuCumAFD.md** (5.50, Accept) — Conformalized Survival Analysis for General Right-Censored Data. Similar topic but without counterfactual component. Accepted despite split reviews (3,8,8,3). Our paper handles a harder problem (counterfactuals) but has a flawed derivation.
- **pVL4bYKOGM.md** (5.50, Reject) — Conformal prediction for causal effects of continuous treatments. Similar conformal+causal structure. Rejected with [6,6,5,5] due to limited evaluation. Our paper has stronger empirical evaluation but weaker derivation rigor.
- **AKAz88zYLB.md** (5.80, Reject) — Conformal Prediction for Dose-Response Models. Similar weighted conformal approach. Rejected with [8,5,3,8,5].
- **4vPVBh3fhz.md** (6.40, Accept) — PAC Prediction Sets Under Label Shift. Cleaner execution, accepted.
- **aJ3tiX1Tu4.md** (6.67, Accept) — Wasserstein-Regularized Conformal Prediction. Stronger theoretical and empirical development, accepted.

**Final score assessment:** The paper makes a genuine contribution by extending conformal survival analysis to counterfactual prediction, with meaningful theoretical results (Theorems 4.1, 4.2) and real clinical validation. However, the flawed derivation in Equation (1) — specifically, the unjustified step (ii) and the wrong inequality direction in step (iii) — is a genuine mathematical error that must be corrected. The "exact" coverage claim is overstated, and the target distribution in the theorems differs from the stated goal. These issues place the paper slightly below the comparable conformal+causal anchors (5.5). With proper correction of the derivation and tempered claims, this could be a solid contribution.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>